Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Glycoproteins Stories

2013-04-16 08:28:59

MONROVIA, Calif. and MELBOURNE, Australia, April 16, 2013 /PRNewswire/ -- Xencor, Inc. announced today that Xencor and CSL Limited have entered into a technology license agreement to provide CSL access to Xencor's Xtend technology to optimize the performance of CSL's monoclonal antibodies. Under the agreement CSL will be granted an exclusive license to utilize Xencor's proprietary Xtend(TM) half-life extension technology in its program against an undisclosed target. Xencor will receive an...

2013-04-13 23:04:03

Diet Doc offers its most advanced hCG diet plans capable of leading patients to a lifetime of improved health. Charlotte, NC (PRWEB) April 13, 2013 A recent report form Science daily informs readers that weight loss, and more specifically, healthy long-term dietary changes can not only affect body weight, but actually alter the body genetically as well. According to a study in Cell Press, subjects who lost significant amounts of weight not only experienced changes in body fat content, but...

2013-04-10 23:00:22

Diet Doc now offers each hCG diet patient unlimited clinical support, nationwide and complimentary during dieting and for up to one year after weight loss has completed. Richmond, VA (PRWEB) April 10, 2013 Diet Doc, in realizing the added benefits of clinical support during dieting, offers each patient complimentary clinical consultations with all in-house staff, including physicians, nurses, nutritionists, and weight loss coaches. The company has adopted this strategy in order to aid...

2013-04-09 12:29:00

BURLINGAME, Calif., April 9, 2013 /PRNewswire/ -- Igenica, Inc., an innovative biopharmaceutical company focused on the discovery and development of first-in-class antibody-based therapeutics for the treatment of cancer, today announced the appointment of Thi-Sau Migone, Ph.D., to the role of Chief Scientific Officer. Dr. Migone brings wide-ranging experience in the discovery and development of novel therapeutic antibodies. Dr. Migone joins Igenica from Human Genome Sciences,...

2013-04-08 20:22:10

TSX Venture: QPT EDMONTON, April 8, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer. The technology was developed by Professor Manuel Penichet and Dr. Tracy...

2013-04-08 12:27:53

ROCKVILLE, Md., April 8, 2013 /PRNewswire/ -- OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications with operations in the United States and China, announced that it has signed a definitive agreement to acquire all the assets of the Life Science business of SDIX(TM) (NASDAQ: SDIX), a leading provider of biotechnology-based products and services. (Logo: http://photos.prnewswire.com/prnh/20130408/DC90285LOGO) "We anticipate the...

2013-04-04 08:28:44

WALTHAM, Mass. and LIANYUNGANG, China, April 4, 2013 /PRNewswire/ -- X-BODY BIOSCIENCES announced today an exclusive alliance with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui"), in which Hengrui will develop and commercialize a novel antibody program generated from X-BODY's antibody platform for Age-related Macular Degeneration (AMD) in Greater China (including mainland China, Taiwan, Macao, and Hong Kong). Under the terms of the collaboration, Hengrui will fund and lead all preclinical...

2013-03-28 08:28:10

ABBOTT PARK, Ill., March 28, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the ARCHITECT AFP test, which may help doctors detect serious birth defects and the progression of testicular cancer, received U.S. Food and Drug Administration (FDA) approval. Biomarkers, such as alpha-fetoprotein (AFP), are substances in the body that physicians can measure to identify the progress of diseases or conditions as well as to evaluate the effectiveness of treatments. AFP has unique traits...

2013-03-25 08:25:56

BREDA, The Netherlands and GHENT, Belgium, March 25, 2013 /PRNewswire/ -- ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development. ARGX-112 is a novel, fully human antibody...

2013-03-21 12:27:50

ROCKVILLE, Md., March 21, 2013 /PRNewswire/ -- OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications, announced the completion of a $21.3 million Series C financing led by Qiming Venture Partners and Kleiner Perkins Caufield Byers China. OriGene's previous investor IDG-Accel also participated in this round. "We are pleased with the high level of commitment and enthusiasm from our new and existing investors. We intend to use the net...